AstraZeneca PLC (LSE:LON:AZN), the UK-based global biopharmaceutical company, disclosed its total voting rights and issued share capital today. In accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, the company announced that as of September 30, 2024, its issued share capital consisted of 1,550,294,658 ordinary shares, each with a nominal value of US$0.25. No shares are held in Treasury, which means the total number of voting rights in the company remains unchanged at 1,550,294,658.
Shareholders may use this figure as the denominator for calculations to determine if they are required to notify their interest in AstraZeneca (NASDAQ:AZN) PLC, or any changes to that interest, under the Disclosure and Transparency Rules.
AstraZeneca, listed on the London, Stockholm, and Nasdaq stock exchanges, is renowned for its focus on the discovery, development, and commercialization of prescription medicines across various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals.
The company's portfolio includes treatments in areas such as Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, AstraZeneca's products are available in over 125 countries and are used by millions of patients globally.
The company has continued to maintain its commitment to innovation in the pharmaceutical industry, while also providing updates on its corporate governance through regular filings such as this one.
This latest announcement was made in a filing with the Securities and Exchange Commission and is part of AstraZeneca's routine regulatory disclosures, ensuring transparency with its investors and the wider market. The company has not reported any changes in its treasury shares or overall voting rights, indicating stability in its share capital structure.
For further details on AstraZeneca's investor relations and media contacts, stakeholders are advised to visit the company's official website or follow its social media channels. The information provided in this article is based on the statements made in the company's Form 6-K filing with the SEC.
In other recent news, AstraZeneca and Daiichi Sankyo's ENHERTU received FDA Priority Review based on results from the DESTINY-Breast06 Phase III trial, potentially evolving the treatment landscape for metastatic breast cancer. However, AstraZeneca's TROPION-Breast01 Phase III trial reported mixed results, with significant improvement in progression-free survival but failing to meet statistical significance in overall survival rates.
On the analyst front, Erste Group revised its rating for AstraZeneca from Buy to Hold following challenges with two potential drugs, while Deutsche Bank, BMO Capital, TD Cowen, and BofA Securities maintained positive outlooks.
AstraZeneca's TAGRISSO gained FDA approval for the treatment of Stage III epidermal growth factor receptor-mutated non-small cell lung cancer, based on the LAURA Phase III trial. This approval marks a significant advancement for patients with this specific type of lung cancer.
Moreover, the FDA approved AstraZeneca's FluMist influenza vaccine for self-administration at home and Fasenra for the treatment of adult patients with a rare immune-mediated vasculitis. These are among the recent developments in the ongoing advancements of AstraZeneca.
InvestingPro Insights
AstraZeneca's strong market position is reflected in its recent financial performance and market valuation. According to InvestingPro data, the company boasts a substantial market capitalization of $242.39 billion, underscoring its significance in the pharmaceutical industry. The company's revenue growth of 10.45% over the last twelve months and a quarterly growth of 13.33% in Q2 2024 demonstrate its continued expansion and market penetration.
InvestingPro Tips highlight AstraZeneca's financial stability and growth potential. The company is expected to see net income growth this year, and analysts predict it will remain profitable. This positive outlook is supported by AstraZeneca's impressive gross profit margin of 82.62%, indicating strong pricing power and efficient cost management.
For income-focused investors, AstraZeneca offers an attractive proposition with its consistent dividend payments. The company has maintained dividend payments for 32 consecutive years, showcasing its commitment to shareholder returns. However, it's worth noting that the current dividend yield stands at 1.26%, which may be considered modest by some investors.
These insights align with the article's portrayal of AstraZeneca as a global leader in biopharmaceuticals with a strong focus on innovation and market presence. The company's stable share capital structure, as mentioned in the article, is complemented by its solid financial performance and growth prospects highlighted by InvestingPro data.
Investors interested in a more comprehensive analysis can access additional tips and metrics through InvestingPro. The platform offers 13 more tips for AstraZeneca, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.